Distinguished in Fibrolamellar Carcinoma

Dr. Brett Fortune

Hepatology
Montefiore Medical Center
111 E 210th St, 
Bronx, NY 
Distinguished in Fibrolamellar Carcinoma
Montefiore Medical Center
111 E 210th St, 
Bronx, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Brett Fortune is a Hepatologist in Bronx, New York. Dr. Fortune is rated as a Distinguished provider by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Ascites, Portal Hypertension, Liver Failure, Liver Transplant, and Hepato-Pancreato-Biliary Surgery.

His clinical research consists of co-authoring 116 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hepatology
Licenses
Internal Medicine in CT
Hospital Affiliations
Montefiore Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetroPlus Health
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VNS Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

MONTEFIORE MEDICAL CENTER
111 E 210th St, Bronx, NY 10467

Additional Areas of Focus

Dr. Fortune has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Extracellular RNA Markers of Liver Disease and Cancer
Extracellular RNA Markers of Liver Disease and Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 06, 2025
Intervention Type: Other
Advancing Liver Therapeutic Approaches (ALTA). The ALTA Consortium Study Group for the Management of Portal Hypertension - A 5-year Longitudinal Observational Study of Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt (TIPS) Placement
Advancing Liver Therapeutic Approaches (ALTA). The ALTA Consortium Study Group for the Management of Portal Hypertension - A 5-year Longitudinal Observational Study of Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt (TIPS) Placement
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2025
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of AXA1665 in Subjects With Liver Cirrhosis and Prior Overt Hepatic Encephalopathy (EMMPOWER)
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of AXA1665 in Subjects With Liver Cirrhosis and Prior Overt Hepatic Encephalopathy (EMMPOWER)
Enrollment Status: Terminated
Publish Date: July 27, 2022
Intervention Type: Drug
Study Drug: AXA1665
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
Enrollment Status: Unknown
Publish Date: March 19, 2019
Intervention Type: Drug
Study Drug: Emricasan
Study Phase: Phase 2
View 3 Less Clinical Trials

113 Total Publications

Guidance for Timely Referral to Liver Transplantation.
Guidance for Timely Referral to Liver Transplantation.
Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Published: April 13, 2025
Similar Doctors
Elite in Fibrolamellar Carcinoma
Dr. Gadi Lalazar
Gastroenterology | Hepatology
Elite in Fibrolamellar Carcinoma
Dr. Gadi Lalazar
Gastroenterology | Hepatology
1305 York Ave Fl 4, 
New York, NY 
 (8.7 miles away)
646-962-4000
Languages Spoken:
English

Gadi Lalazar is a Gastroenterologist and a Hepatologist in New York, New York. Dr. Lalazar is rated as a Distinguished provider by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Fibrolamellar Carcinoma, Nonalcoholic Steatohepatitis (NASH), Non-Alcoholic Fatty Liver Disease, and Liver Cancer.

Distinguished in Fibrolamellar Carcinoma
Dr. Hyung L. Kim
Hepatology
Distinguished in Fibrolamellar Carcinoma
Dr. Hyung L. Kim
Hepatology

Icahn School Of Medicine At Mount Sinai

1 Gustave L Levy Pl, 
New York, NY 
 (7.2 miles away)
212-241-8545
Languages Spoken:
English
See accepted insurances

Hyung Kim is a Hepatologist in New York, New York. Dr. Kim is rated as a Distinguished provider by MediFind in the treatment of Fibrolamellar Carcinoma. Her top areas of expertise are Hepatitis, Autoimmune Hepatitis, Fibrolamellar Carcinoma, Cirrhosis, and Endoscopy.

Distinguished in Fibrolamellar Carcinoma
Dr. Joseph Odin
Hepatology
Distinguished in Fibrolamellar Carcinoma
Dr. Joseph Odin
Hepatology

Icahn School Of Medicine At Mount Sinai

5 E 98th St, 
New York, NY 
 (7.4 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joseph Odin is a Hepatologist in New York, New York. Dr. Odin is rated as a Distinguished provider by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Primary Biliary Cholangitis, Cholangitis, Hepatitis, Endoscopy, and Liver Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Fortune's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile